-
公开(公告)号：WO2022123006A1
公开(公告)日：2022-06-16
申请号：PCT/EP2021/085191
申请日：2021-12-10
IPC分类号： C12N7/02
摘要： Methods of purifying adenovirus that can be performed on a large scale. The methods purify adenovirus from an adenovirus-containing sample comprising or derived from a host cell population by clarifying the sample, wherein clarification comprises depth filtration followed by microfiltration; processing the clarified sample by anion exchange chromatography; and processing the anion exchange product by tangential flow filtration (TFF) to provide a TFF product.
-
公开(公告)号：WO2022101826A1
公开(公告)日：2022-05-19
申请号：PCT/IB2021/060458
申请日：2021-11-11
摘要： Described herein are stable pharmaceutical formulations for bioactive agents, including macromolecular bioactive agents such as polynucleotides and polypeptides. Also provided are medicaments and treatments using the pharmaceutical formulations described herein, as well as kits and methods of treating, preventing or managing a disease or disorder using the pharmaceutical formulations described herein.
-
公开(公告)号：WO2022074617A1
公开(公告)日：2022-04-14
申请号：PCT/IB2021/059232
申请日：2021-10-08
IPC分类号： A61K31/496 , A61K31/498 , A61K31/4985 , A61K39/395 , A61P35/00 , A61P35/02 , C07D401/12 , C07D471/04
摘要： A pharmaceutical product for administration of an anti-HER2 antibody-drug conjugate in combination with a PARP1 selective inhibitor is provided. The anti-HER2 antibody drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the antibody-drug conjugate and the PARP1 selective inhibitor are administered in combination to a subject: Formula (I).
-
4.发明申请
公开(公告)号：WO2019241590A1
公开(公告)日：2019-12-19
申请号：PCT/US2019/037096
申请日：2019-06-13
IPC分类号： G16H20/10 , G16H10/20 , G16H50/20 , A61K31/41 , A61K31/4178 , A61K31/4184 , A61K31/4245 , A61P9/12
摘要： A method is provided for lowering blood pressure in a subject in need thereof by administering an angiotensin II receptor blocker pharmaceutical composition to a subject qualified for over-the-counter access to the angiotensin II receptor blocker pharmaceutical composition. In some embodiments, the angiotensin II receptor blocker pharmaceutical composition includes azilsartan medoxomil, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, or valsartan. In some embodiments, the angiotensin II receptor blocker pharmaceutical composition comprises an active ingredient that is (5-methyl-2-oxo- 1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4- yl]methyl}-1H-benzimidazole-7-carboxylate or a pharmaceutically acceptable salt thereof.
-
5.发明申请
公开(公告)号：WO2019241585A1
公开(公告)日：2019-12-19
申请号：PCT/US2019/037091
申请日：2019-06-13
发明人： SKELLY, Richard L. , FIROR, Judy
摘要： A method is provided for treating erectile dysfunction in a subject in need thereof by administering a cGMP-specific phosphodiesterase 5 (PDE 5 ) inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the PDE 5 inhibitor pharmaceutical composition. In some embodiments, the PDE 5 inhibitor pharmaceutical composition includes tadalafil or vardenafil.
-
公开(公告)号：WO2019241576A1
公开(公告)日：2019-12-19
申请号：PCT/US2019/037080
申请日：2019-06-13
IPC分类号： G16H20/10 , G16H10/20 , G16H50/20 , A61K31/115 , A61P3/10
摘要： A method is provided for lowering blood sugar in a subject in need thereof by administering a biguanide anti -hyperglycemic pharmaceutical composition to a subject qualified for over-the-counter access to the biguanide anti-hyperglycemic pharmaceutical composition. In some embodiments, the biguanide anti-hyperglycemic pharmaceutical composition includes Ν,Ν-dimethylimidodicarbonimidic diamide, or a pharmaceutically acceptable salt thereof. In some embodiments, the biguanide anti-hyperglycemic pharmaceutical composition includes metformin hydrochloride.
-
7.发明申请
公开(公告)号：WO2019241574A1
公开(公告)日：2019-12-19
申请号：PCT/US2019/037078
申请日：2019-06-13
IPC分类号： G16H20/10 , G16H10/20 , G16H50/20 , A61K31/403 , A61K31/4985 , A61K31/513 , A61K31/522 , A61P3/10
摘要： A method is provided for lowering blood sugar in a subject in need thereof by administering a dipeptidyl peptidase-4 inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the dipeptidyl peptidase-4 inhibitor pharmaceutical composition. In some embodiments, the dipeptidyl peptidase-4 inhibitor pharmaceutical composition includes saxagliptin, sitagliptin, linagliptin, alogliptin, or a pharmaceutically acceptable salt thereof. In some embodiments, the dipeptidyl peptidase-4 inhibitor pharmaceutical composition includes (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1- adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile or a pharmaceutically acceptable salt thereof.
-
8.发明申请
公开(公告)号：WO2019241519A1
公开(公告)日：2019-12-19
申请号：PCT/US2019/036977
申请日：2019-06-13
发明人： SKELLY, Richard, L. , FIROR, Judy
IPC分类号： G16H20/10 , G16H10/20 , G16H50/20 , A61K31/4422 , A61P9/12
摘要： A method is provided for lowering blood pressure in a subject in need thereof by administering a dihydropyridine-type calcium channel blocker pharmaceutical composition to a subject qualified for over-the-counter access to the dihydropyridine-type calcium channel blocker pharmaceutical composition. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes isradipine, nifedipine, or nisoldipine. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2- chlorophenyl)-6-methyl-l,4-dihydropyridine-3,5-dicarboxylate or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：WO2018115100A1
公开(公告)日：2018-06-28
申请号：PCT/EP2017/083774
申请日：2017-12-20
发明人： SKELLY, Richard , FIROR, Judy , GUIGA, David , MONGAN, William , PRYBOLSKY, Robert , BLASETTO, James
摘要： Systems and methods are provided for over the counter statin delivery to a subject. 5 Survey results from the subject are run against a first plurality of filters. When a filter in the first plurality of filters is fired, the subject is deemed not qualified. The survey results are also run against a second plurality of filters. When a respective filter in the second plurality is fired, the subject is provided with a corresponding warning. The method proceeds to a fulfillment process when no filter in the first plurality fires and the subject has acknowledged each warning associated with each fired filter in the second plurality. The fulfillment stores the composition order, communicates a drug facts label for the statin to the subject, and authorizes, upon subject confirmation that the label has been read, provision of the statin to the subject, the authorization including a destination associated with the subject.
-
10.发明申请IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER 审中-公开咪唑并[4,5-C]喹啉-2-酮化合物及其在治疗癌症中的应用
公开(公告)号：WO2015170081A1
公开(公告)日：2015-11-12
申请号：PCT/GB2015/051312
申请日：2015-05-05
IPC分类号： C07D471/04 , A61K31/437 , A61P35/00
CPC分类号： C07D471/04 , A61K31/444 , A61K31/4545 , A61K31/4745 , A61K31/502 , A61K45/06
摘要： The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where Q, R 1 , R 2 , R 3 , R 4 and R 5 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5- c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.
摘要翻译： 本说明书通常涉及式（I）的化合物及其药学上可接受的盐，其中Q，R 1，R 2，R 3，R 4和R 5具有本文定义的任何含义。 本说明书还涉及这些化合物及其盐在治疗或预防ATM激酶介导的疾病（包括癌症）中的应用。 本说明书还涉及咪唑并[4,5-c]喹啉-2-酮化合物及其药学上可接受的盐的结晶形式; 包含这些化合物和盐的药物组合物; 包含这些化合物和盐的试剂盒; 制备这种化合物和盐的方法; 可用于制造这种化合物和盐的中间体; 以及使用这些化合物和盐来治疗ATM激酶介导的疾病（包括癌症）的方法。
-
-
-
-
-
-
-
-
-
搜索结果
972 条记录 (耗时 0.02 秒)
